Completed PHASE3 INTERVENTIONAL NCT00261599

An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy

A Phase 3, Randomized, Double-Blind, Dose-Controlled Study to Assess the Efficacy and Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal to Moderate Sedation in Patients Undergoing Colonoscopy

Sponsor: Eisai Inc.

Conditions Conscious Sedation

Interventions AQUAVAN® (fospropofol disodium) Injection Midazolam HCI

Updated 6 times since 2017 Last updated: Nov 6, 2008 Started: Mar 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00261599, this PHASE3 trial focuses on Conscious Sedation and remains completed. Sponsored by Eisai Inc., it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States , Chevy Chase, United States , Evansville, United States , Fresno, United States , Germantown, United States , Huntsville, United States , Indianapolis, United States , Jackson, United States , Jacksonville, United States , Laurel, United States and 10 more locations